Novo Nordisk: Financial report for the period 1 Ja
Post# of 301275
Posted On: 10/31/2013 2:45:12 AM
Novo Nordisk: Financial report for the period 1 January 2013 to 30 September 2013. Increased operating profit by 10% in the first nine months of 2013
Sales growth of 8% driven by Victoza(®), Levemir(®) and NovoRapid(®) Sales increased by 13% in local currencies and by 8% in Danish kroner to DKK 61.9 billion. ? Sales of modern insulins increased by 15% (10% in Danish kroner). ? Sales of Victoza(®) increased by 28% (24% in Danish kroner). ? Sales in North America increased by 20% (17% in Danish kroner). ? Sales in International Operations increased by 15% (8% in Danish kroner). [HUG#1739405]
(0)
(0)